Europe
Promore Pharma AB announces that the new share issue with preferential rights for existing shareholders has been completed.
Eisai Co., Ltd. has announced that LENVIMA, the orally available kinase inhibitor discovered by Eisai, has been accepted by the National Medical Products Administration of China for an application for the additional indication of differentiated thyroid cancer.
As a global leading supplier of of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics launches a large range of foodborne pathogen antibodies and antigens, which have been validated to work in various types of immunoassays and can be supplied as high quality tools for the detection of foodborne pathogens.
The Institute of Cancer Research, London, welcomes the approval by NICE of the innovative targeted cancer treatment palbociclib for women with advanced breast cancer who have already received hormone therapy.
Proteros biostructures GmbH announced that Rodin Therapeutics, Inc., a Boston, MA based biotech company developing novel, small molecule therapeutics for synaptopathies has been acquired by Alkermes plc, a global biopharmaceutical company headquartered in Dublin, Ireland.
Vivoryon Therapeutics AG, announced its third quarter business update for the period ending September 30, 2019.
A new report urges biomedical researchers to use online web resources very carefully, taking into account their complementary benefits and weaknesses, when selecting small-molecule chemical probes to help answer their research questions.
Recipharm announced today ongoing large-scale commercial manufacturing of RedHill Biopharma’s (Nasdaq: RDHL) drug, Talicia® (omeprazole magnesium, amoxicillin and rifabutin) delayed-release capsules 10 mg[1]/250 mg/12.5 mg, for its planned launch in the first quarter 2020.
Submission follows completion of a Clinical Endpoint study
Data show that the implantation procedure of the Genio® system is relatively non-invasive
PRESS RELEASES